CGON (CG Oncology) Additional Paid-In Capital : $957.18 Mil(As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Additional Paid-In Capital?

CG Oncology's quarterly additional paid-in capital increased from Sep. 2024 ($722.95 Mil) to Dec. 2024 ($951.35 Mil) and increased from Dec. 2024 ($951.35 Mil) to Mar. 2025 ($957.18 Mil).

CG Oncology's annual additional paid-in capital increased from Dec. 2022 ($3.64 Mil) to Dec. 2023 ($6.84 Mil) and increased from Dec. 2023 ($6.84 Mil) to Dec. 2024 ($951.35 Mil).

CG Oncology Additional Paid-In Capital Historical Data

The historical data trend for CG Oncology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Additional Paid-In Capital Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

3.27

3.64

6.84

951.35

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial						715.81	718.13	722.95	951.35	957.18

CG Oncology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

CG Oncology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CG Oncology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.